BTK and mantle cell lymphoma: Therefore, there is currently ongoing randomized, open-label, worldwide phase III research comparing pirtobrutinib monotherapy to ibrutinib, acalabrutinib, or zanubrutinib in patients with previously treated, BTK inhibitor-naive MCL (NCT04662255).